Advancing Immunotherapy in the Global Oncology Landscape The current trajectory of global oncology
The global biopharmaceutical landscape is currently undergoing a radical transformation as the
A strategic collaboration between Orbis Medicines and Novo Nordisk is currently focused on finding oral solutions for metabolic and cardiovascular diseases. This partnership signifies a broader shift in the biotechnology landscape, where the historical reliance on painful injections for chronic
The tendency of clustering algorithms to fluctuate between different partitions creates a reproducibility crisis that necessitates a standardized, unsupervised solution. In the complex world of single-cell transcriptomics, the ability to accurately categorize individual cells into distinct
While Stochastic Optical Reconstruction Microscopy achieves nanoscopic precision, the quality of
Machine learning models have identified N-terminal pro-B-type natriuretic peptide as the most

The partnership between Eli Lilly and NVIDIA to build a supercomputer capable of running trillions of molecular simulations is a signal that biopharma’s approach to drug discovery is changing at a s…

Over the past few years, applying AI to drug discovery has become a crowded, well-funded field. In

The move from research-level discovery to established clinical use is a critical juncture that

The biopharma playbook is being actively rewritten. After years of chasing breakthrough science at

In 2026, boards and customers are asking a direct question: can promising science be turned into
Americans will accept artificial intelligence for some routine work in medicine, a new Pew Research Center survey found. But Americans get less comfortable when AI handles medical decisions without a person checking the work, and that leaves hospitals and health tech companies with two things to
The brain tumor microenvironment is notoriously immunologically cold, utilizing inhibitory
The emergence of "agentic" scientific exploration allows AI agents to autonomously set up